Germany's Rentschler looks to build UK footprint with five-year investment in cell and gene therapies

Conner Mitchell

Looking to add another capability to its arsenal, German CDMO Rentschler Biopharma will bump up its investment in cell and gene therapies over the next …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Germany's Rentschler looks to build UK footprint with five-year investment in cell and gene therapies

Conner Mitchell

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Ger­many's Rentschler looks to build UK foot­print with five-year in­vest­ment in cell and gene ther­a­pies

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Germany's Rentschler looks to build UK footprint with five-year investment in cell and gene therapies